About Mitochondrial import receptor subunit TOM22 homolog
Mitochondrial import receptor subunit TOM22 homolog (TOMM22) is a protein
from Homo sapiens identified by UniProt accession
Q9NS69, 142 residues long.
MolForge cross-references it against 0 known binders and
91 disease associations.
Target properties
| Protein name | Mitochondrial import receptor subunit TOM22 homolog |
|---|
| UniProt accession | Q9NS69 |
|---|
| Gene | TOMM22 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 142 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (91)
Diseases linked to this target (Open Targets).
- triglyceride measurement · score 0.09
- Blackfan-Diamond anemia · score 0.08
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome · score 0.08
- alpha thalassemia-intellectual disability syndrome type 1 · score 0.07
- Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16 · score 0.07
- delta-beta-thalassemia · score 0.06
- hemoglobin D disease · score 0.06
- hemoglobin E-beta-thalassemia syndrome · score 0.06
- Alpha-thalassemia · score 0.05
- Beta-thalassemia · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NS69-F1 | alphafold | PREDICTED | 71.15 | — |
Amino-acid sequence (142 residues)
MAAAVAAAGA GEPQSPDELL PKGDAEKPEE ELEEDDDEEL DETLSERLWG LTEMFPERVR SAAGATFDLS LFVAQKMYRF SRAALWIGTT SFMILVLPVV FETEKLQMEQ QQQLQQRQIL LGPNTGLSGG MPGALPSLPG KI
Explore Mitochondrial import receptor subunit TOM22 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets